Information Provided By: 
Fly News Breaks for March 16, 2018
JAZZ
Mar 16, 2018 | 06:24 EDT
Leerink analyst Ami Fadia says her firm's physician survey indicates adoption of Jazz Pharmaceuticals' Vyxeos is "ramping up nicely especially in the outpatient setting." The analyst remains confident that Vyxeos sales will grow to $150M in 2018, in-line with consensus and at the high-end of management's guidance. She reiterates an Outperform rating on Jazz shares with a $180 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
